Portal de Periódicos da CAPES

Opioid-Induced Sleep Apnea: Is It a Real Problem?

2012; American Academy of Sleep Medicine; Volume: 08; Issue: 05 Linguagem: Inglês

10.5664/jcsm.2162

1550-9397

Winfried Randerath, Sandhya George,

Sleep and related disorders

Free AccessCPAPOpioid-Induced Sleep Apnea: Is It a Real Problem? Winfried J. Randerath, M.D., Sandhya George Winfried J. Randerath, M.D. Address correspondence to: Winfried J. Randerath, M.D., Professor of Medicine, Institute of Pneumology at the University Witten/Herdecke, Clinic for Pneumology and Allergology, Center of Sleep Medicine and Respiratory Care, Bethanien Hospital, Solingen, Germany0049 212 63 60000049 212 63 6005 E-mail Address: [email protected] Institute of Pneumology at the University Witten/Herdecke, Clinic for Pneumology and Allergology, Center of Sleep Medicine and Respiratory Care, Bethanien Hospital, Solingen, Germany , Sandhya George Institute of Pneumology at the University Witten/Herdecke, Clinic for Pneumology and Allergology, Center of Sleep Medicine and Respiratory Care, Bethanien Hospital, Solingen, Germany Published Online:October 15, 2012https://doi.org/10.5664/jcsm.2162Cited by:13SectionsPDF ShareShare onFacebookTwitterLinkedInRedditEmail ToolsAdd to favoritesDownload CitationsTrack Citations AboutINTRODUCTIONIn 1997 the American Academy of Pain Medicine and the American Pain Society stated that "it is now accepted…that respiratory depression induced by opioids tends to be a short lived phenomenon, generally occurs only in opioid-naïive patients and is antagonized by pain. Therefore, withholding the appropriate use of opioids from a patient who is experiencing pain on the basis of respiratory concerns is unwarranted."1 In addition, Papaleontiou et al. published a meta-analysis in 2010 on the efficacy and safety of opioid intake in chronic non-cancer pain.2 Constipation, nausea, and dizziness represented the top three side effects, with a prevalence between 22% and 30%. However, obstructive or central apnea/hypopnea, hypoventilation during sleep, and impairment of respiratory drive remained unmentioned.2Can general practitioners, pain therapists and oncologists reassure their patients regarding respiratory side effects in long-term treatment with opioids?It is without doubt, that for far too long sufficient palliation has been withheld from pain patients, in fear of side effects, addiction, and misuse of opioids. However, improved knowledge combined with changing attitudes has helped to normalize the use of the most important relievers of pain, leading to a large increase in opioid prescription.3,4 Moreover, opioids are prescribed not only to relieve pain, but also, for example to alleviate dyspnea in patients with chronic pulmonary disorders.5 Finally, opiate addiction remains a growing and largely unsolved problem, leading to the incorporation of an increasing number of patients world-wide in methadone maintenance programs.6 Bearing in mind this widened use of opioids, observations of sleep related breathing disorders (SRBD) are alarming. Kelly et al. described fatal or life-threatening events in children who underwent adenotonsillectomy for obstructive sleep apnea. These children possessed genetic alterations that led to an increased morphine production from codeine.7 Many such reports of perioperative complications in sleep apnea patients have been published.In 2007 the broad spectrum of SRBD under opioids were described retrospectively by Walker et al.8 Besides obstructive disturbances, they found central apneas, ataxic or irregular respiration, and periods of sustained hypoventilation.However, we have to admit frankly that our knowledge of the pathophysiology of opioid-induced sleep apnea is still very limited. Pattinson reviewed the control of respiration under opioid intake.9 The author pointed out that respiration becomes shallow and irregular leading to hypercapnia and hypoxia. The respiratory disturbances differed according to the mode of application. Whereas rapid intravenous boli induced apneas, long-term infusions led to a gradual increase of hypercapnia, thereby contributing to the maintenance of respiration. The effect of opioids on the respiratory rhythm has not been conclusively explored. Peripheral and central chemosensitivity play a major role, leading to a reduction of the hypoxic and hypercapnic ventilatory response. However, the extent of the interference and the precise location of the interception of the reflexes are unclear. This retards the pharmaceutical development of opioids with sufficient analgesic properties but minimized respiratory side effects.Having said all this, physicians will mostly be interested in data relating to the clinical presentation, optimal diagnosis, and treatment of opioid-induced sleep apnea. Are there specific signs and symptoms of opioid induced sleep apnea? They are certainly associated with dizziness, impaired concentration, and daytime sleepiness. But is it possible to differentiate between central nervous system effects and breathing disturbances? Generally speaking, sleepiness and deficits in neurocognitive parameters cease during long-term application, so that even driving may be permitted. However, this trend is not to be expected in SRBD. Another clinically relevant but unsolved problem is the question of whether the outcome of opioid users with or without SRBD differs.In this current issue, Ramar et al.10 present an important study focusing on the question of the best available therapy of respiratory disturbances during sleep. They investigated patients with central breathing disturbances due to chronic heart failure or chronic opioid use, who had failed to respond to treatment with constant CPAP. Adaptive servoventilation (ASV) enabled sufficient therapy in the majority of heart failure and opioid patients. The study provides preliminary data, as it was retrospective and a randomized comparison with CPAP, placebo, or optimal pharmaceutical therapy is missing. Nevertheless, the authors analyze the largest sample to date from everyday practice, and in that sense, it is representative of the real-life situation.In 2008 two studies with contradictory results were published in this journal.2 While Farney failed to show a difference between CPAP and ASV, Javaheri found an effective treatment with ASV in a small group of opioid induced sleep apnea patients. The latter results, now being proven by Ramar's data, could be expected due to the algorithm of adaptive servoventilation. CPAP may interfere with SRBD in several ways: it stabilizes the upper airways and counterbalances upper airway obstruction; the positive thoracic pressure reduces left ventricular cardiac afterload and therefore improves the ejection fraction; and finally, CPAP can enlarge lung volumes and reduce ventilation- perfusion mismatch. However, CPAP does not influence, or only marginally influences breathing rhythm and chemosensitivity. In contrast, ASV combines the effects of CPAP (positive expiratory pressure) with variable pressure support and the application of mandatory breaths. Therefore, disturbances of respiratory drive and periods of hypoventilation can be counterbalanced. Interestingly, a higher bicarbonate level was a predictor of ASV success. This surprising finding could have, as discussed by the authors, technical reasons. However, it could also indicate extensive periods of hypoventilation as a part of the SRBD. Based on Ramar's data, the question remains why 30% to 40% of patients with heart failure or opioid induced sleep apnea, respectively, could not be treated optimally. The choice or setting of the device, the mode of reaction of the algorithm, and interface problems may contribute to this phenomenon. However, the results suggest an advantage to the early use of adaptive servoventilation after optimal medical therapy.Sleep specialists should try to avoid repeating history. The epochal invention of CPAP by Sullivan led to a rather generalized perception of obstructive sleep apnea, but importantly at the same time, to the implementation of the optimal treatment. This coincidence—although of huge value for the patient—handicapped detailed exploration of the pathophysiological background. Opioid-induced sleep apnea is, as pointed out above, even more unclear. Increasing evidence in this field suggests a treatment advantage with adaptive servoventilation. However, all efforts should be undertaken to better understand the clinical presentation, pathophysiology, and prognosis. Opioid-induced sleep apnea is a real problem as the rapidly increasing prevalence indicates. We are however a long way from truly understanding its relevance.Future studies should try to characterize the different phenotypes of breathing disturbances as precisely as possible. This also has implications for coming guidelines.DISCLOSURE STATEMENTDr. Randerath has received speaking fees and research support from Weinmann, Respironics, Resmed, Heinen und Löwenstein. Sandhya George has indicated no financial conflicts of interest.CITATIONRanderath WJ; George S. Opioid-induced sleep apnea: is it a real problem? J Clin Sleep Med 2012;8(5):577-578.REFERENCES1 The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain SocietyClin J Pain19971368, 9084947Google Scholar2 Papaleontiou MHenderson CRTurner BJ, et al.Outcomes associated with opioid use in the treatment of chronic noncancer pain in older adults: a systematic review and meta-analysisJ Am Geriatr Soc201058135369, 20533971CrossrefGoogle Scholar3 Sullivan MDEdlund MJFan MY, et al.Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP studyPain20081384409, 18547726CrossrefGoogle Scholar4 Caudill-Slosberg MASchwartz LMWoloshin SOffice visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000Pain20041095149, 15157714CrossrefGoogle Scholar5 Rocker GHorton RCurrow DGoodridge DYoung JBooth SPalliation of dyspnoea in advanced COPD: revisiting a role for opioidsThorax2009649105, 19786716CrossrefGoogle Scholar6 Sharkey KMKurth MEAnderson BJCorso RPMillman RPStein MDObstructive sleep apnea is more common than central sleep apnea in methadone maintenance patients with subjective sleep complaintsDrug Alcohol Depend20101087783, 20079978CrossrefGoogle Scholar7 Kelly LERieder Mvan den Anker J, et al.More codeine fatalities after tonsillectomy in North American childrenPediatrics2012129e13437, 22492761CrossrefGoogle Scholar8 Walker JMFarney RJRhondeau SM, et al.Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathingJ Clin Sleep Med2007345561, 17803007LinkGoogle Scholar9 Pattinson KTOpioids and the control of respirationBr J Anaesth200810074758, 18456641CrossrefGoogle Scholar10 Ramar KRamar PMorgenthaler TIAdaptive servoventilation in patients with central or complex sleep apnea related to chronic opioid use and congestive heart failureJ Clin Sleep Med2012856976LinkGoogle Scholar11 Javaheri SMalik ASmith JChung EAdaptive pressure support servoventilation: a novel treatment for sleep apnea associated with use of opioidsJ Clin Sleep Med2008430510, 18763420LinkGoogle Scholar12 Farney RJWalker JMBoyle KMCloward TVShilling KCAdaptive servoventilation (ASV) in patients with sleep disordered breathing associated with chronic opioid medications for non-malignant painJ Clin Sleep Med200843119, 18763421LinkGoogle Scholar Previous article Next article FiguresReferencesRelatedDetailsCited byStill just the tip of the icebergOwens R Journal of Clinical Sleep Medicine, Vol. 16, No. S1, (9-10), Online publication date: 17-Dec-2020. Masterplan 2025 der Österreichischen Gesellschaft für Pneumologie (ÖGP) – die erwartete Entwicklung und Versorgung respiratorischer Erkrankungen in ÖsterreichMasterplan 2025 of the Austrian Society of Pneumology (ASP)—the expected burden and management of respiratory diseases in AustriaStudnicka M, Baumgartner B, Bolitschek J, Doberer D, Eber E, Eckmayr J, Hartl S, Hesse P, Jaksch P, Kink E, Kneussl M, Lamprecht B, Olschewski H, Pfleger A, Pohl W, Prior C, Puelacher C, Renner A, Steflitsch W, Stelzmüller I, Täubl H, Vonbank K, Wagner M, Wantke F and Wass R Wiener klinische Wochenschrift, 10.1007/s00508-020-01722-w, Vol. 132, No. S3, (89-113), Online publication date: 1-Sep-2020. Obstructive Sleep Apnea in Psychiatric InpatientsTanielian M, Doghramji K and Certa K The Journal of Nervous and Mental Disease, 10.1097/NMD.0000000000001129, Vol. 208, No. 3, (190-193), Online publication date: 1-Mar-2020. Sleep and AnesthesiaSong J, Um Y, Kim T, Kim S, Kwon S and Hong S Sleep Medicine Research, 10.17241/smr.2018.00164, Vol. 9, No. 1, (11-19), Online publication date: 30-Jun-2018. Opioide in der HausarztpraxisPain treatment with opioids for non-cancer pain by the family physicianSchüning J, Maier C and Schwarzer A MMW - Fortschritte der Medizin, 10.1007/s15006-017-9599-0, Vol. 159, No. S3, (52-61), Online publication date: 1-Nov-2017. Can drugs induce or aggravate sleep apneas? A case-noncase study in VigiBase ® , the WHO pharmacovigilance database Linselle M, Sommet A, Bondon-Guitton E, Moulis F, Durrieu G, Benevent J, Rousseau V, Chebane L, Bagheri H, Montastruc F and Montastruc J Fundamental & Clinical Pharmacology, 10.1111/fcp.12264, Vol. 31, No. 3, (359-366), Online publication date: 1-Jun-2017. Effects on breathing of agonists to μ-opioid or GABA A receptors dialyzed into the ventral respiratory column of awake and sleeping goatsLanger T, Neumueller S, Crumley E, Burgraff N, Talwar S, Hodges M, Pan L and Forster H Respiratory Physiology & Neurobiology, 10.1016/j.resp.2017.01.007, Vol. 239, , (10-25), Online publication date: 1-May-2017. Opioids for restless legs syndromede Oliveira C, Carvalho L, Carlos K, Conti C, de Oliveira M, Prado L and Prado G Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006941.pub2 Medium Increased Risk for Central Sleep Apnea but Not Obstructive Sleep Apnea in Long-Term Opioid Users: A Systematic Review and Meta-AnalysisFiliatrault M, Chauny J, Daoust R, Roy M, Denis R and Lavigne G Journal of Clinical Sleep Medicine, Vol. 12, No. 04, (617-625), Online publication date: 15-Apr-2016. Sleep-disordered breathing decreases after opioid withdrawalSchwarzer A, Aichinger-Hinterhofer M, Maier C, Vollert J and Walther J PAIN, 10.1097/j.pain.0000000000000279, Vol. 156, No. 11, (2167-2174), Online publication date: 1-Nov-2015. Drugs and Sleep Apneas? A review of the French Pharmacovigilance databaseLinselle M, Montastruc F, Jantzen H, Valnet-Rabier M, Haramburu F, Coquerel A, Gouraud A, Perault-Pochat M, Bagheri H and Montastruc J Therapies, 10.2515/therapie/2014218, Vol. 70, No. 4, (347-350), Online publication date: 1-Jul-2015. Adaptive Servoventilation in Central Sleep ApneaRanderath W and Javaheri S Sleep Medicine Clinics, 10.1016/j.jsmc.2013.11.001, Vol. 9, No. 1, (69-85), Online publication date: 1-Mar-2014. Opioid-Induced Central Sleep ApneaJavaheri S and Randerath W Sleep Medicine Clinics, 10.1016/j.jsmc.2013.10.003, Vol. 9, No. 1, (49-56), Online publication date: 1-Mar-2014. Volume 08 • Issue 05 • October 15, 2012ISSN (print): 1550-9389ISSN (online): 1550-9397Frequency: Monthly Metrics History Submitted for publicationSeptember 1, 2012Accepted for publicationSeptember 1, 2012Published onlineOctober 15, 2012 Information© 2012 American Academy of Sleep MedicinePDF download